Michael Hertl

Summary

Affiliation: Philipps University
Country: Germany

Publications

  1. pmc T cell control in autoimmune bullous skin disorders
    Michael Hertl
    Department of Dermatology and Allergology, Philipps University, Marburg, Germany
    J Clin Invest 116:1159-66. 2006
  2. pmc Targeted immunotherapy with rituximab leads to a transient alteration of the IgG autoantibody profile in pemphigus vulgaris
    Ralf Muller
    Department of Dermatology and Allergology, University of Marburg, D 35033 Marburg, Germany
    Dermatol Res Pract 2010:321950. 2010
  3. ncbi request reprint Rapid improvement of recalcitrant disseminated granuloma annulare upon treatment with the tumour necrosis factor-alpha inhibitor, infliximab
    M S Hertl
    Department of Dermatology, University Hospital of Erlangen Nürnberg, Hartmannstr 14, D 91052 Erlangen, Germany
    Br J Dermatol 152:552-5. 2005
  4. doi request reprint [Autoimmune bullous skin disorders]
    Michael Hertl
    Klinik für Dermatologie und Allergologie, Marburg
    Ther Umsch 67:465-82. 2010
  5. doi request reprint Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases
    Michael Hertl
    Department of Dermatology and Allergology, University Clinic of Giessen and Marburg GmbH, Marburg, Germany
    J Dtsch Dermatol Ges 6:366-73. 2008
  6. doi request reprint Research in practice: Treatment of autoimmune bullous disorders
    Michael Hertl
    Department of Dermatology and Allergy, University of Marburg, Germany
    J Dtsch Dermatol Ges 7:500-5. 2009
  7. pmc Desmoglein 3-specific T regulatory 1 cells consist of two subpopulations with differential expression of the transcription factor Foxp3
    Christian Veldman
    Department of Dermatology, University of Marburg, Marburg, Germany
    Immunology 127:40-9. 2009
  8. ncbi request reprint Ex vivo analysis of desmoglein 1-responsive T-helper (Th) 1 and Th2 cells in patients with pemphigus foliaceus and healthy individuals
    Kerstin L Gebhard
    Department of Dermatology, University of Erlangen, Erlangen, Germany
    Exp Dermatol 14:586-92. 2005
  9. doi request reprint IgA autoantibodies in the pemphigoids and linear IgA bullous dermatosis
    Barbara Horvath
    Philipps University, Department of Dermatology and Allergology, Marburg, Germany
    Exp Dermatol 19:648-53. 2010
  10. ncbi request reprint IgG against extracellular subdomains of desmoglein 3 relates to clinical phenotype of pemphigus vulgaris
    Ralf Muller
    Department of Dermatology and Allergology, University of Marburg, Marburg, Germany
    Exp Dermatol 17:35-43. 2008

Collaborators

Detail Information

Publications71

  1. pmc T cell control in autoimmune bullous skin disorders
    Michael Hertl
    Department of Dermatology and Allergology, Philipps University, Marburg, Germany
    J Clin Invest 116:1159-66. 2006
    ....
  2. pmc Targeted immunotherapy with rituximab leads to a transient alteration of the IgG autoantibody profile in pemphigus vulgaris
    Ralf Muller
    Department of Dermatology and Allergology, University of Marburg, D 35033 Marburg, Germany
    Dermatol Res Pract 2010:321950. 2010
    ..Thus, in PV, rituximab only temporarily depletes pathogenic B cell responses against distinct subdomains of Dsg3 which reappear upon clinical relapse...
  3. ncbi request reprint Rapid improvement of recalcitrant disseminated granuloma annulare upon treatment with the tumour necrosis factor-alpha inhibitor, infliximab
    M S Hertl
    Department of Dermatology, University Hospital of Erlangen Nürnberg, Hartmannstr 14, D 91052 Erlangen, Germany
    Br J Dermatol 152:552-5. 2005
    ..Infliximab may be an additional option in the treatment of recalcitrant forms of GA as well as in other chronic granulomatous skin disorders, such as sarcoidosis and necrobiosis lipoidica...
  4. doi request reprint [Autoimmune bullous skin disorders]
    Michael Hertl
    Klinik für Dermatologie und Allergologie, Marburg
    Ther Umsch 67:465-82. 2010
    ..Comparable controlled therapeutic trials have not yet been performed in dermatitis herpetiformis and epidermolysis bullosa acquisita...
  5. doi request reprint Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases
    Michael Hertl
    Department of Dermatology and Allergology, University Clinic of Giessen and Marburg GmbH, Marburg, Germany
    J Dtsch Dermatol Ges 6:366-73. 2008
    ..The present consensus statement of German-speaking dermatologists, rheumatologists and oncologists summarizes and evaluates the current evidence for the use and mode of application of rituximab in autoimmune bullous skin disorders...
  6. doi request reprint Research in practice: Treatment of autoimmune bullous disorders
    Michael Hertl
    Department of Dermatology and Allergy, University of Marburg, Germany
    J Dtsch Dermatol Ges 7:500-5. 2009
    ..The ultimate therapeutic goal is anergy induction in these autoaggressive T cells which inititate and perpetuate the B cell-driven immune pathogenesis of pemphigus and the pemphigoids...
  7. pmc Desmoglein 3-specific T regulatory 1 cells consist of two subpopulations with differential expression of the transcription factor Foxp3
    Christian Veldman
    Department of Dermatology, University of Marburg, Marburg, Germany
    Immunology 127:40-9. 2009
    ..Thus, our observations suggest a distinct relationship between Dsg3-specific Tr1 and Th-like cells which may be critical for the continuous generation and survival of Dsg3-specific Tr1 cells...
  8. ncbi request reprint Ex vivo analysis of desmoglein 1-responsive T-helper (Th) 1 and Th2 cells in patients with pemphigus foliaceus and healthy individuals
    Kerstin L Gebhard
    Department of Dermatology, University of Erlangen, Erlangen, Germany
    Exp Dermatol 14:586-92. 2005
    ..Moreover, both Th1 and Th2 cells were present in patients and healthy donors, suggesting that the loss of B-cell tolerance against Dsg1 in PF is not exclusively determined by the presence of autoaggressive T cells...
  9. doi request reprint IgA autoantibodies in the pemphigoids and linear IgA bullous dermatosis
    Barbara Horvath
    Philipps University, Department of Dermatology and Allergology, Marburg, Germany
    Exp Dermatol 19:648-53. 2010
    ..Patients with linear IgA bullous dermatosis (LABD) have IgA autoantibodies against a 97/120-kDa protein which is highly homologous to a shedded fragment of the BP180-ectodomain...
  10. ncbi request reprint IgG against extracellular subdomains of desmoglein 3 relates to clinical phenotype of pemphigus vulgaris
    Ralf Muller
    Department of Dermatology and Allergology, University of Marburg, Marburg, Germany
    Exp Dermatol 17:35-43. 2008
    ..The findings may help to define more refined serological disease markers of PV...
  11. doi request reprint Birch pollen immunotherapy leads to differential induction of regulatory T cells and delayed helper T cell immune deviation
    Christian Möbs
    Department of Dermatology and Allergology, Philipps University Marburg, Marburg, Germany
    J Immunol 184:2194-203. 2010
    ....
  12. doi request reprint T and B cells target identical regions of the non-collagenous domain 1 of type VII collagen in epidermolysis bullosa acquisita
    Ralf Muller
    Department of Dermatology and Allergology, Philipps University Deutschhausstrasse 9, D 35033 Marburg, Germany
    Clin Immunol 135:99-107. 2010
    ....
  13. ncbi request reprint Autoreactive T and B cells from bullous pemphigoid (BP) patients recognize epitopes clustered in distinct regions of BP180 and BP230
    Sybille Thoma-Uszynski
    Department of Dermatology, Friedrich Alexander University, Erlangen, Germany
    J Immunol 176:2015-23. 2006
    ..These observations support the concept that BP180, but not BP230, is the primary autoantigen of BP critical for disease development...
  14. doi request reprint Clinical activity of pemphigus vulgaris relates to IgE autoantibodies against desmoglein 3
    Angela Nagel
    Department of Dermatology and Allergology, Philipps University Marburg, Germany
    Clin Immunol 134:320-30. 2010
    ..Thus, dsg3-specific IgE and IgG4 autoantibodies are related to acute onset disease which provides additional support to the concept that PV is a Th2-driven autoimmune disorder...
  15. ncbi request reprint IgG reactivity against non-conformational NH-terminal epitopes of the desmoglein 3 ectodomain relates to clinical activity and phenotype of pemphigus vulgaris
    Ralf Muller
    Department of Dermatology, University of Marburg, Marburg, Germany
    Exp Dermatol 15:606-14. 2006
    ....
  16. doi request reprint Rituximab exerts a dual effect in pemphigus vulgaris
    Rüdiger Eming
    Department of Dermatology and Allergology, Philipps University, Marburg, Germany
    J Invest Dermatol 128:2850-8. 2008
    ..Our findings indicate that the response to rituximab in PV involves two mechanisms: (1) the depletion of autoreactive B cells and (2) the herein demonstrated, presumably specific downregulation of dsg3-specific CD4(+) Th cells...
  17. ncbi request reprint Detection of laminin 5-specific auto-antibodies in mucous membrane and bullous pemphigoid sera by ELISA
    Vassiliki Bekou
    Department of Dermatology, Friedrich Alexander University Erlangen Nurnberg, Erlangen, Germany
    J Invest Dermatol 124:732-40. 2005
    ..Thus, the established LN5 ELISA holds great promise as a novel diagnostic and prognostic parameter for MMP...
  18. ncbi request reprint BP230- and BP180-specific auto-antibodies in bullous pemphigoid
    Sybille Thoma-Uszynski
    Department of Dermatology, Friedrich Alexander University, Erlangen Nurnberg, Germany
    J Invest Dermatol 122:1413-22. 2004
    ..Collectively, the global diagnostic properties of the BP180-ELISA outperform those of the BP230-ELISA. Presence of BP230 auto-reactivity, however, supports the diagnosis of BP and might be indicative for the extent of the disease...
  19. doi request reprint Birch pollen immunotherapy results in long-term loss of Bet v 1-specific TH2 responses, transient TR1 activation, and synthesis of IgE-blocking antibodies
    Christian Möbs
    Department of Dermatology and Allergology, Philipps University Marburg, Marburg, Germany
    J Allergy Clin Immunol 130:1108-1116.e6. 2012
    ....
  20. doi request reprint Rituximab mediates a strong elevation of B-cell-activating factor associated with increased pathogen-specific IgG but not autoantibodies in pemphigus vulgaris
    Angela Nagel
    Department of Dermatology and Allergology, Philipps University, Marburg, Germany
    J Invest Dermatol 129:2202-10. 2009
    ....
  21. ncbi request reprint Type I regulatory T cells specific for desmoglein 3 are more frequently detected in healthy individuals than in patients with pemphigus vulgaris
    Christian Veldman
    Department of Dermatology, University of Erlangen Nurnberg, Erlangen, Germany
    J Immunol 172:6468-75. 2004
    ....
  22. doi request reprint IgE recognition of bullous pemphigoid (BP)180 and BP230 in BP patients and elderly individuals with pruritic dermatoses
    Luca Fania
    Department of Dermatology and Allergology, Philipps University of Marburg, Marburg, Germany
    Clin Immunol 143:236-45. 2012
    ..Thus, IgE recognition of the BP autoantigens is presumably an early pathogenetic event in BP...
  23. doi request reprint Autoimmune bullous skin diseases. Part 2: diagnosis and therapy
    Andrea Kneisel
    Department of Dermatology and Allergy, University Clinic Marburg, Germany
    J Dtsch Dermatol Ges 9:927-47. 2011
    ..This review presents a state-of-the-art algorithm for making the diagnosis of autoimmune bullous disorders and provides an overview on currently available therapeutic options...
  24. doi request reprint Autoimmune bullous skin diseases. Part 1: Clinical manifestations
    Andrea Kneisel
    Department of Dermatology and Allergy, University Clinic Marburg, Germany
    J Dtsch Dermatol Ges 9:844-56; quiz 857. 2011
    ..The intention of the review is to demonstrate the heterogeneous clinical spectrum of autoimmune bullous disorders...
  25. doi request reprint Results of a survey of German dermatologists on the therapeutic approaches to pemphigus and bullous pemphigoid
    Silke C Hofmann
    Department of Dermatology, University Medical Center Freiburg, Hauptstrasse 7Freiburg D 79104, Germany
    J Dtsch Dermatol Ges 7:227-33. 2009
    ..The aim of this survey was to assess the current treatment standards at German dermatological hospitals and the need for future therapeutic trials...
  26. doi request reprint Clinical and immunological follow-up of pemphigus patients on adjuvant treatment with immunoadsorption or rituximab
    Martin Pfütze
    Department of Dermatology and Allergology, Philipps University, Marburg, Germany
    Dermatology 218:237-45. 2009
    ..Novel therapeutic strategies such as immunoadsorption (IA) or the anti-CD20 antibody rituximab (Rtx) hold promise to be effective in severe or recalcitrant PV...
  27. pmc Development of an ELISA for sensitive and specific detection of IgA autoantibodies against BP180 in pemphigoid diseases
    Kinga Csorba
    Department of Dermatology, University of Freiburg, Hauptstrasse 7, 79104, Freiburg, Germany
    Orphanet J Rare Dis 6:31. 2011
    ..Therefore, the aim of the present study was to develop an ELISA to detect IgA autoantibodies against collagen XVII in the sera of patients with pemphigoids...
  28. pmc IgG autoantibodies against desmocollin 3 in pemphigus sera induce loss of keratinocyte adhesion
    David Rafei
    Department of Dermatology and Allergology, Philipps University, Marburg, Germany
    Am J Pathol 178:718-23. 2011
    ..These findings demonstrate that IgG autoantibodies against an additional component of the desmosomes, Dsc3, induce loss of keratinocyte adhesion and thus may contribute to blister formation in pemphigus...
  29. ncbi request reprint Inhibition of the transcription factor Foxp3 converts desmoglein 3-specific type 1 regulatory T cells into Th2-like cells
    Christian Veldman
    Department of Dermatology, University of Erlangen Nurnberg, Erlangen, Germany
    J Immunol 176:3215-22. 2006
    ..In conclusion, Foxp3 expression is inherent to Tr1 function, and modulation of Foxp3 expression in autoaggressive Th2 cells may provide a novel therapeutic approach aimed at restoring tolerance against Dsg3 in PV...
  30. ncbi request reprint Recommendations for the use of immunoapheresis in the treatment of autoimmune bullous diseases
    Detlef Zillikens
    Department of Dermatology, University of Lubeck, Germany
    J Dtsch Dermatol Ges 5:881-7. 2007
    ..A consensus meeting was held in mid-2005 in Hamburg, aiming at developing guidelines for the use of immunoapheresis in the treatment of autoimmune bullous diseases. This paper summarizes the experts' recommendations...
  31. ncbi request reprint Prolonged clinical remission of patients with severe pemphigus upon rapid removal of desmoglein-reactive autoantibodies by immunoadsorption
    Rüdiger Eming
    Department of Dermatology, University Hospital of Erlangen, Erlangen, Germany
    Dermatology 212:177-87. 2006
    ..Therapeutic removal of Dsg-reactive autoantibodies by immunoadsorption (IA) has been demonstrated to exert clinical remission of the disease...
  32. pmc Prevalence of collagen VII-specific autoantibodies in patients with autoimmune and inflammatory diseases
    Emilia Licarete
    Department of Dermatology, University of Freiburg, Hauptstr, 7, Freiburg 79104, Germany
    BMC Immunol 13:16. 2012
    ..The aim of our present study was to develop an accurate immunoassay for assessing the presence of autoantibodies against collagen VII in large cohorts of patients and healthy donors...
  33. doi request reprint B-cell-directed therapy for inflammatory skin diseases
    Angela Nagel
    Department of Dermatology and Allergology, Philipps University, Marburg, Germany
    J Invest Dermatol 129:289-301. 2009
    ..Future translational and clinical investigations are mandatory to precisely define the role and the contribution of impaired B-cell function in (auto)immune-mediated skin diseases...
  34. ncbi request reprint T-cellular autoimmunity against desmogleins in pemphigus, an autoantibody-mediated bullous disorder of the skin
    Michael Hertl
    Department of Dermatology, University of Erlangen Nurnberg, Hartmannstr 14, D 91054 Erlangen, Germany
    Autoimmun Rev 2:278-83. 2003
    ..These findings strongly suggest that (1) Dsg3-reactive Th2 cells are restricted to PV, (2) distinct HLA class II alleles are critical for T cell recognition of Dsg3, and (3) Ab production is associated with both, Th1 and Th2 cells...
  35. ncbi request reprint Severity and phenotype of bullous pemphigoid relate to autoantibody profile against the NH2- and COOH-terminal regions of the BP180 ectodomain
    SilkeC Hofmann
    Department of Dermatology, Friedrich Alexander University Erlangen Nurnberg, Germany
    J Invest Dermatol 119:1065-73. 2002
    ....
  36. ncbi request reprint Detection of low avidity desmoglein 3-reactive T cells in pemphigus vulgaris using HLA-DR beta 1*0402 tetramers
    Christian Veldman
    Department of Dermatology and Allergology, University of Marburg, Deutschhausstrasse 9, D 35033 Marburg, Germany
    Clin Immunol 122:330-7. 2007
    ..The findings of this study suggest that HLA class II tetramers may provide a highly specific approach to monitor ex vivo the T cellular autoimmune response against Dsg3 in patients with PV...
  37. doi request reprint Comorbidities, metabolic risk profile and health-related quality of life in German patients with plaque-type psoriasis: a cross-sectional prospective study
    Arnd Jacobi
    Department of Dermatology and Allergology, Philipps University Marburg, Marburg, Germany
    Int J Dermatol 52:1081-7. 2013
    ..There is still a gap between treatment options and quality of care. The purpose of this study was to determine the demographic data, comorbidities, and the limitations of quality of life in patients with plaque-type psoriasis...
  38. doi request reprint Efficacy and safety of rituximab in pemphigus: experience of the German Registry of Autoimmune Diseases
    Michael Kasperkiewicz
    Department of Dermatology, University of Lubeck, Ratzeburger Allee 160, Lubeck, Germany
    J Dtsch Dermatol Ges 10:727-32. 2012
    ..However, no systematic evaluation is available to corroborate this observation. The aim of this study was to systematically determine efficacy and safety of rituximab in treatment-resistant pemphigus...
  39. ncbi request reprint Autoimmune bullous disorders
    Rüdiger Eming
    Klinik für Dermatologie und Allergologie, Philipps Universitat Marburg, Marburg, Germany
    Clin Chem Lab Med 44:144-9. 2006
    ..Most of the autoantigens are available as recombinant proteins, which allows for autoantibody screening by ELISA or immunoblot analysis to confirm the primary diagnosis and, importantly, for immunoserological follow-up of patients...
  40. ncbi request reprint Introducing a novel Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) in pemphigus
    Martin Pfütze
    Department of Dermatology and Allergology, Philipps University, Marburg, Deutschhausstrasse 9, 35037 Marburg, Germany
    Eur J Dermatol 17:4-11. 2007
    ..Taking this challenge into account we introduce and discuss a newly developed autoimmune bullous skin disorder intensity score (ABSIS)...
  41. doi request reprint Herpes simplex virus infection in pemphigus vulgaris: clinical and immunological considerations
    Giacomo Caldarola
    Department of Dermatology and Allergology, Philipp Universität, Marburg, Germany
    Eur J Dermatol 18:440-3. 2008
    ....
  42. ncbi request reprint Mucous membrane pemphigoid: clinical aspects, immunopathological features and therapy
    Daniela Bruch-Gerharz
    Department of Dermatology, Heinrich Heine University, Duesseldorf, Germany
    Eur J Dermatol 17:191-200. 2007
    ..The short-term clinical and pathological manifestations of disease activity have been reduced by new therapies, although the degree of long-term benefit from these treatments awaits further study...
  43. doi request reprint Induction of T regulatory cells by the superagonistic anti-CD28 antibody D665 leads to decreased pathogenic IgG autoantibodies against desmoglein 3 in a HLA-transgenic mouse model of pemphigus vulgaris
    Thomas Schmidt
    Department of Dermatology and Allergology, Philipps University Marburg, Marburg, Germany
    Exp Dermatol 25:293-8. 2016
    ..These observations confirm the powerful immune regulatory functions of Treg cells and identify Treg cells as potential therapeutic modulators in PV...
  44. ncbi request reprint Clinical response of severe mechanobullous epidermolysis bullosa acquisita to combined treatment with immunoadsorption and rituximab (anti-CD20 monoclonal antibodies)
    Andrea Niedermeier
    Klinik für Dermatologie und Allergologie, Universitätsklinikum Giessen und Marburg, Philipps Universitat, Marburg, Germany
    Arch Dermatol 143:192-8. 2007
    ..We describe herein the therapeutic response of 2 patients with recalcitrant mechanobullous EBA to combined treatment with immunoadsorption and rituximab, an anti-CD20 monoclonal antibody that induces depletion of B cells in vivo...
  45. ncbi request reprint T cell recognition of desmoglein 3 peptides in patients with pemphigus vulgaris and healthy individuals
    Christian M Veldman
    Department of Dermatology, University of Erlangen Nurnberg, Erlangen, Germany
    J Immunol 172:3883-92. 2004
    ..These findings demonstrate that T cell recognition of distinct Dsg3 peptides is restricted by distinct HLA class II molecules and is independent from the development of pemphigus vulgaris...
  46. doi request reprint Melanoma-associated chondroitin sulphate proteoglycan as a new target antigen for CD4+ T cells in melanoma patients
    Cornelia Erfurt
    Department of Dermatology, University Hospital Erlangen, Erlangen, Germany
    Int J Cancer 124:2341-6. 2009
    ..Our findings suggest that vaccination against MCSP helper T cell epitopes might be a promising approach to fight melanoma...
  47. ncbi request reprint Immunoadsorption in pemphigus
    Rüdiger Eming
    Department of Dermatology and Allergology, University Hospital, Philipps University, Marburg, Germany
    Autoimmunity 39:609-16. 2006
    ..IA in pemphigus is generally safe and well tolerated...
  48. ncbi request reprint Deficiency of PORCN, a regulator of Wnt signaling, is associated with focal dermal hypoplasia
    Karl Heinz Grzeschik
    Department of Human Genetics, University of Marburg, Bahnhofstr 7, 35033 Marburg, Germany
    Nat Genet 39:833-5. 2007
    ..The findings implicate FDH as a developmental disorder caused by a deficiency in PORCN...
  49. ncbi request reprint Delayed response of oral pemphigus vulgaris to rituximab treatment
    Andrea Niedermeier
    Universitätsklinikum Giessen und Marburg, Klinik für Dermatologie und Allergologie, Standort Marburg
    Eur J Dermatol 16:266-70. 2006
    ..The delayed clinical response to rituximab of the present case may be explained by the persistence of long-lived plasma cells that continued to produce pathogenic autoantibodies against desmoglein 3...
  50. doi request reprint European Guidelines (S1) on the use of high-dose intravenous immunoglobulin in dermatology
    Alexander Enk
    Department of Dermatology, Ruprecht Karls University Heidelberg, Germany
    J Dtsch Dermatol Ges . 2016
    ..Because first-line use is limited by the high costs of IVIg, the first clinical guidelines on the use of IVIg in dermatological conditions were established in 2008 and renewed in 2011...
  51. pmc Increased Frequency of T Follicular Helper Cells and Elevated Interleukin-27 Plasma Levels in Patients with Pemphigus
    Tina Hennerici
    Department of Dermatology and Allergology, Philipps University Marburg, Marburg, Germany
    PLoS ONE 11:e0148919. 2016
    ..The further characterization of IL-21-producing T cells and of the role of IL-27 will lead to a more defined understanding of the auto-ab response in pemphigus. ..
  52. pmc CD3-positive B cells: a storage-dependent phenomenon
    Angela Nagel
    Department of Dermatology and Allergology, Philipps University Marburg, Marburg, Germany Institute of Clinical and Molecular Virology, Friedrich Alexander Universitat Erlangen Nurnberg, Erlangen, Germany
    PLoS ONE 9:e110138. 2014
    ....
  53. doi request reprint Pimecrolimus 1% cream in the treatment of facial psoriasis: a 16-week open-label study
    Arnd Jacobi
    Department of Dermatology, University Hospital Marburg, Marburg, Germany
    Dermatology 216:133-6. 2008
    ..Facial psoriasis requires a treatment approach other than topical corticosteroids which bear the risk of skin atrophy. Topical pimecrolimus has been shown to be effective in atopic eczema and recently in psoriasis...
  54. doi request reprint Cellular and humoral mechanisms of immune tolerance in immediate-type allergy induced by specific immunotherapy
    Christian Möbs
    Department of Dermatology and Allergology, Philipps University, Marburg, Germany
    Int Arch Allergy Immunol 147:171-8. 2008
    ..Thus, the fine balance between allergen-specific T helper 2 and T reg cells constitutes a critical factor for the successful treatment of ITA by SIT...
  55. doi request reprint Lichenoid exanthema mimicking graft-versus-host disease associated with obstructive lung disease in a non-transplanted patient
    Franziska Carola Eberle
    Department of Dermatology and Allergology, Philipps University, Deutschhausstr 9, D 35037 Marburg, Germany
    Eur J Dermatol 20:381-5. 2010
    ..The immune pathogenesis that caused the skin and lung disease in this patient remains unclear. Multiple pregnancies with two abortions with the potential induction of microchimerism may play a role in the disease pathogenesis...
  56. ncbi request reprint Infliximab in the treatment of moderate to severe atopic dermatitis
    Arnd Jacobi
    Department of Dermatology, University of Erlangen Nurnberg, Erlangen, Germany
    J Am Acad Dermatol 52:522-6. 2005
    ..Chronic use of standard therapies for atopic dermatitis (AD) is associated with variable efficacy and potential side effects. Targeted therapeutic approaches, such as the inhibition of tumor necrosis factor-alpha, may be a novel option...
  57. doi request reprint Pathogenic IgG antibodies against desmoglein 3 in pemphigus vulgaris are regulated by HLA-DRB1*04:02-restricted T cells
    Rüdiger Eming
    Department of Dermatology and Allergology, Philipps University, D 35043 Marburg, Germany
    J Immunol 193:4391-9. 2014
    ..Finally, these results identify Dsg3-reactive CD4(+) T cells as potential therapeutic targets in the future. ..
  58. ncbi request reprint Type I regulatory T cells in autoimmunity and inflammatory diseases
    Christian Veldman
    Department of Dermatology, University of Marburg, Marburg, Germany
    Int Arch Allergy Immunol 140:174-83. 2006
    ..The recent development of methods allowing the ex vivo expansion of regulatory T cells may be the first step towards a cellular therapy with regulatory T cells to control T-cell-mediated pathology in inflammatory disorders...
  59. ncbi request reprint Risk factors for lethal outcome in patients with bullous pemphigoid: low serum albumin level, high dosage of glucocorticosteroids, and old age
    Berthold Rzany
    Department of Dermatology, Fakultät für Klinische Medizin Mannheim der Universität Heidelberg, Mannheim, Germany
    Arch Dermatol 138:903-8. 2002
    ..Although bullous pemphigoid (BP) is the most frequent autoimmune bullous disease and is associated with a considerable case-fatality rate, little is known about factors that influence its prognosis...
  60. ncbi request reprint CHILD syndrome in 3 generations: the importance of mild or minimal skin lesions
    Mario Bittar
    Department of Dermatology and Center of Human Genetics, University of Marburg, Marburg, Germany
    Arch Dermatol 142:348-51. 2006
    ..We present here a family with mild features of CHILD syndrome in 3 generations. Molecular analysis was used to confirm the diagnosis...
  61. ncbi request reprint Rituximab (anti-CD20 monoclonal antibody)--ultimate or first choice in pemphigus?
    Michael Hertl
    Dermatology 214:275-7. 2007
  62. ncbi request reprint [Therapeutic application of TNF-alpha inhibitors infliximab and etanercept in inflammatory skin disorders]
    Arnd Jacobi
    Dermatologische Klinik mit Poliklinik der Universität Erlangen Nürnberg
    J Dtsch Dermatol Ges 1:259-72. 2003
    ....
  63. doi request reprint Multicenter prospective study of the humoral autoimmune response in bullous pemphigoid
    Giovanni Di Zenzo
    Istituto Dermopatico dell Immacolata, Molecular and Cell Biology Laboratory, IDI IRCCS, Rome, Italy
    Clin Immunol 128:415-26. 2008
    ..These results demonstrate the usefulness of the combined ELISAs based on various BP180 and BP230 fragments in establishing the diagnosis of BP and support the concept that BP180 is the major autoantigen of BP...
  64. ncbi request reprint Dichotomy of autoreactive Th1 and Th2 cell responses to desmoglein 3 in patients with pemphigus vulgaris (PV) and healthy carriers of PV-associated HLA class II alleles
    Christian Veldman
    Departments of Dermatology, University of Erlangen Nurnberg, Erlangen, Germany
    J Immunol 170:635-42. 2003
    ....
  65. ncbi request reprint A single cycle of rituximab for the treatment of severe pemphigus
    Pascal Joly
    Rouen University Hospital, Rouen, France
    N Engl J Med 357:545-52. 2007
    ..The aim of this study was to assess the efficacy of a single cycle of rituximab in severe types of pemphigus...
  66. pmc Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus
    Dedee F Murrell
    Department of Dermatology at St George Hospital, University of NSW, Sydney, Australia
    J Am Acad Dermatol 58:1043-6. 2008
    ..These should assist in development of consistent reporting of outcomes in future studies...
  67. doi request reprint Allergological approach to drug hypersensitivity reactions
    Bernhard Przybilla
    Klinik und Poliklinik fur Dermatologie und Allergologie, Ludwig Maximilians Universität Frauenlobstr 9 1180337 Munich, Germany
    J Dtsch Dermatol Ges 6:240-3. 2008
  68. ncbi request reprint [The use of high dose intravenous immunoglobulins in dermatology]
    Alexander Enk
    Univ Hautkliniken Mainz
    J Dtsch Dermatol Ges 1:183-90. 2003
    ..This manuscript documents the expert consensus on the use of IVIG in dermatology and reflects current clinical practice. It should be a guideline for the practitioner for the use of IVIG in dermatologic diseases...
  69. ncbi request reprint Rowell syndrome with palmoplantar involvement and suspected epitope spreading
    Alessandra Marini
    Acta Derm Venereol 87:278-80. 2007
  70. ncbi request reprint [Significant decrease in quality of life in patients with pemphigus vulgaris. Results from the German Bullous Skin Disease (BSD) Study Group]
    Franziska Mayrshofer
    Dermatologische Klinik mit Poliklinik, Friedrich Alexander Universitat, Erlangen Nurnberg, Germany
    J Dtsch Dermatol Ges 3:431-5. 2005
    ..Clinically characteristic are painful chronic blisters or erosions of mucous membranes and skin. There are no published studies on the impact o this disease on quality of life...
  71. ncbi request reprint Pemphigus vulgaris localized to the nose and cheeks
    Can Baykal
    Department of Dermatology, Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey
    J Am Acad Dermatol 47:875-80. 2002
    ..In the other patient, antibodies against desmoglein-3 were detected by enzyme-linked immunosorbent assay. These localized lesions may represent a subgroup of pemphigus vulgaris or a period of limited activity during this chronic disease...